Novo Nordisk and Photys Therapeutics Partner for $186M Cardiometabolic Collaboration Using PHICS Technology

Novo Nordisk has entered into a collaboration with Photys Therapeutics to advance its cardiometabolic pipeline utilizing Photys' innovative PHICS (Phosphorylation Inducing Chimeric Small molecules) technology, marking a significant investment up to $186 million, including potential milestone payments[1][2]. This partnership aims to develop new therapeutics by bringing kinases into proximity with disease-causing proteins to modulate their activity through phosphorylation, targeting an unspecified cardiometabolic condition[1][2]. Photys will oversee preclinical development, while the Danish pharmaceutical leader will manage clinical development, as part of its strategy to deepen its focus in cardiometabolic fields beyond diabetes and obesity[1][2].